All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
The MDS Hub is pleased to present a visual abstract summarizing the key updates and changes in the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Updates include the grouping of myelodysplastic syndromes (MDS) entities as genetically or morphologically defined and the addition of MDS-SF3B1, MDS-5q, and MDS-biTP53 as genetically defined subtypes. Terminology describing the types of childhood MDS have been revised and the diagnostic criteria for chronic myelomonocytic leukemia have been amended.
To download this visual abstract, click below.Download here
International Consensus Classification of MDS: 2022 updates
We summarize the key points from the new ICC of myeloid neoplasms, in particular referring to MDS. The new ICC represents a major revision from previous classification systems.
Targeted sequencing of seven genes may improve classification of MDS
The National Myelodysplastic Syndromes (MDS) Natural History Study (NCT02775383) is a collaborative study involving the National Heart, Lung, and Blood Institute (NHLBI), National...
Subscribe to get the best content related to MDS delivered to your inbox